Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARK D BORCHELT

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1194776286
CMS profile
368889
Location
GULFPORT, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$68,341.03

323 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 7; records 51–100 of 323 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARK D BORCHELT

NPI 1194776286 · CMS profile ID 368889

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

GULFPORT, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 323 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194776286?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARK D BORCHELT, NPI 1194776286, CMS profile ID 368889. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 323 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194776286?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MARK D BORCHELT, NPI 1194776286, CMS profile ID 368889. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 323 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194776286?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MARK D BORCHELT, NPI 1194776286, CMS profile ID 368889, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 323 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1194776286?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

323 matching records · $68,341.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 323 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 323.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mannkind Corporation $4.8510/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752667881 CMS
Medtronic MiniMed, Inc. $14.2110/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 730116647 CMS
SANOFI-AVENTIS U.S. LLC $13.2010/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744105485 CMS
Amgen Inc. $13.9010/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741212659 CMS
Zealand Pharma US, Inc. $18.4210/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739667795 CMS
Abbott Laboratories $9.9410/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749012899 CMS
AstraZeneca Pharmaceuticals LP $20.2710/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736151659 CMS
Lilly USA, LLC $15.4210/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728530689 CMS
Lilly USA, LLC $13.3410/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728537377 CMS
Novo Nordisk Inc $229.5010/05/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745066309 CMS
SANOFI-AVENTIS U.S. LLC $9.8110/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744105477 CMS
Lilly USA, LLC $17.7010/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728534147 CMS
Amneal Pharmaceuticals LLC $13.7109/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719979751 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $12.7109/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720715169 CMS
Radius Health, Inc. $13.3609/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746308893 CMS
Novo Nordisk Inc $1,261.9309/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744975929 CMS
Abbott Laboratories $8.9609/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749012895 CMS
AstraZeneca Pharmaceuticals LP $15.0409/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736400445 CMS
Amgen Inc. $11.3509/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741212657 CMS
Merck Sharp & Dohme Corporation $19.6109/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747762471 CMS
Novo Nordisk Inc $45.8909/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744981459 CMS
Novo Nordisk Inc $2,632.5009/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744981463 CMS
Novo Nordisk Inc $2,632.5009/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744981473 CMS
Novo Nordisk Inc $74.1809/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744981475 CMS
SANOFI-AVENTIS U.S. LLC $20.0009/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744105475 CMS
Corcept Therapeutics $18.8109/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744746147 CMS
Novo Nordisk Inc $10.5509/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744981461 CMS
Novo Nordisk Inc $16.4409/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744981471 CMS
Novo Nordisk Inc $2,767.5009/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744975927 CMS
Mannkind Corporation $11.4209/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752667879 CMS
Abbott Laboratories $0.3509/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749012889 CMS
Abbott Laboratories $18.2709/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749012893 CMS
Novo Nordisk Inc $14.4809/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744975925 CMS
AstraZeneca Pharmaceuticals LP $20.4009/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735800525 CMS
Lilly USA, LLC $21.7209/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728554955 CMS
Novo Nordisk Inc $15.0009/04/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744975923 CMS
Merck Sharp & Dohme Corporation $18.7609/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747762455 CMS
Lilly USA, LLC $15.3509/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728537373 CMS
Mannkind Corporation $17.9209/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752667877 CMS
Amgen Inc. $21.2608/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741212655 CMS
RECORDATI_RARE_DISEASES_INC. $3.5708/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740083539 CMS
Amgen Inc. $15.9508/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741212653 CMS
SANOFI-AVENTIS U.S. LLC $5.1808/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744105473 CMS
Mannkind Corporation $21.6208/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752667875 CMS
Insulet Corporation $24.9608/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748421389 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.5708/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720715173 CMS
Becton, Dickinson and Company $15.8308/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748083879 CMS
Radius Health, Inc. $7.4408/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746308863 CMS
Corcept Therapeutics $12.5508/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744746141 CMS
Amgen Inc. $13.2208/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741212661 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $159,796.51 523
PY2020 $68,341.03 323
PY2021 $59,623.84 285
PY2022 $175,870.07 511
PY2023 $100,012.86 411
PY2024 $96,051.88 358
PY2025 $62,571.95 278

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $199,265.30 78
PY2024 Principal investigator $48.50 1
PY2023 Recipient $436.50 1
PY2023 Principal investigator $19,485.00 6
PY2022 Recipient $291.00 1
PY2022 Principal investigator $36,697.00 6
PY2021 Recipient $1,013.56 1
PY2021 Principal investigator $58,140.77 11
PY2020 Recipient $3,242.54 1
PY2020 Principal investigator $21,786.73 14
PY2019 Recipient $2,056.52 1
PY2019 Principal investigator $49.45 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652242
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 12/17/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652244
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 12/17/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652246
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,595.40 12/15/2025 Non-covered Recipient Entity
The National Diabetes And Obesity Research Institute At Tradition Mis
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808579
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652226
Principal investigator 1 Boehringer Ingelheim International GmbH $21.50 12/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652228
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 12/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652230
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652232
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652234
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652236
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652238
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652240
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,508.80 11/13/2025 Non-covered Recipient Entity
The National Diabetes And Obesity Research Institute At Tradition Mis
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808577
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652214
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652216
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652218
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652220
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652222
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652224
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652202
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652204
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652206
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652208
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652210
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652212
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/29/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220794233
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 09/24/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652194
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 09/24/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652196
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 09/24/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652198
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 09/24/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652200
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,780.00 09/18/2025 Non-covered Recipient Entity
The National Diabetes And Obesity Research Institute At Tradition Mis
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808575
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652166
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652168
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652170
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652172
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652174
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652192
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 08/20/2025 Non-covered Recipient Entity
The National Diabetes And Obesity Research Institute At Tradition Mis
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808571
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,162.50 08/06/2025 Non-covered Recipient Entity
The National Diabetes And Obesity Research Institute At Tradition Mis
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808573
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652156
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652158
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652160
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652162
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652164
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652186
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652190
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652176
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652178
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652180
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652182
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652184
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652188
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,651.20 06/26/2025 Non-covered Recipient Entity
The National Diabetes And Obesity Research Institute At Tradition Mis
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808569
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652140
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652142
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652144
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652146
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652148
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652150
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 05/27/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652152
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 05/27/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652154
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652128
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652130
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652132
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652134
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652136
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652138
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652114
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652116
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652118
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652120
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652122
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652126
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
National Diabetes And Obesity Research Institute At Tradition
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220652124
Principal investigator 1 Eli Lilly and Company $4,609.62 03/25/2025 Non-covered Recipient Entity
NATIONAL DIABETES & OBESITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187885060
Principal investigator 1 Eli Lilly and Company $804.03 03/25/2025 Non-covered Recipient Entity
NATIONAL DIABETES & OBESITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187885062
Principal investigator 1 Eli Lilly and Company $106,264.00 01/21/2025 Non-covered Recipient Entity
NATIONAL DIABETES & OBESITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187887000
Principal investigator 1 Eli Lilly and Company $55,255.00 01/07/2025 Non-covered Recipient Entity
NATIONAL DIABETES & OBESITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187884884